RT Journal Article
SR Electronic
T1 Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.29.21254588
DO 10.1101/2021.03.29.21254588
A1 Bell, Melanie L
A1 Catalfamo, Collin J
A1 Farland, Leslie V.
A1 Ernst, Kacey C
A1 Jacobs, Elizabeth T
A1 Klimentidis, Yann C
A1 Jehn, Megan
A1 Pogreba-Brown, Kristen
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254588.abstract
AB Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as post-acute sequelae of SAR-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of various symptoms of PASC, defined as experiencing at least one symptom 30 days or longer. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30-250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95%CI 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress (30.8%). The median number of symptoms was 3 (range 1-20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.frontiersin.org/articles/10.3389/fpubh.2021.620060/full Funding StatementThis study has been funded by a seed grant awarded by the BIO5 Institute at the University of Arizona. The sponsors have no role or authority over the design or implementation of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the University of Arizona Institutional Review Board (Protocol #2003521636A002).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to privacy and ethical considerations, data are not publicly available.